. Author manuscript; available in PMC: 2014 Jan 1.

Published in final edited form as: Breast Cancer Res Treat. 2012 Dec 6;137(2):449–455. doi: 10.1007/s10549-012-2366-0

Table 2.

HER2 Hazard Ratios by HR Status, Years since Diagnosis, and Site of Recurrence

Site	0 – 4 years		4 – 8 years		8 – 12 years
Site	HR−	HR+	HR−	HR+	HR−	HR+
Brain	1.2 (0.9, 1.6)	3.2 (2.3, 4.4)	1.9 (1.1, 32)	2.8 (1.8, 4.5)	0.0 (0.0, 0.0)	1.8 (0.8, 4.0)
Liver	1.1 (0.9, 1.4)	1.6 (1.2, 2.0)	1.2 (0.6, 2.5)	1.5 (1.0, 2.2)	0.9 (0.1, 9.0)	1.1 (0.5, 2.6)
Lung	0.8 (0.6, 1.0)	1.5 (1.1, 2.0)	0.5 (0.3, 1.0)	1.5 (0.9, 2.3)	0.4 (0.0, 3.1)	1.1 (0.4, 3.3)
Pleura	0.6 (0.4, 0.9)	1.1 (0.7, 1.8)	0.6 (0.3, 1.3)	1.2 (0.7, 2.2)	5.1 (0.5, 57)	0.7 (0.2, 2.3)
Bone	0.7 (0.6, 1.0)	1.4 (1.1, 1.7)	0.7 (0.3, 1.4)	0.7 (0.5, 1.1)	0.0 (0.0, 0.0)	0.8 (0.4, 1.7)
DLN^*	0.6 (0.4, 0.8)	1.6 (1.2, 2.3)	0.8 (0.4, 1.5)	1.0 (0.6, 1.5)	0.4 (0.0, 3.2)	0.9 (0.3, 2.6)

DLN = distant lymph node

Numbers in parentheses are 95% confidence intervals for the hazard ratios.